Rapamycin's Longest Human Trial Missed Its Primary Endpoint. The Muscle It Did Build Went to the Women.
Rapamycin occupies a position no other longevity compound holds. It has extended median and maximum lifespan in genetically heterogeneous mice repeatedly, at multiple doses, in both sexes, in independent laboratories, starting as late as 20 months of age, which in mouse terms is roughly a 60-year-old human. A 2025 meta-analysis in Aging Cell pooled lifespan data across eight vertebrate species and found rapamycin produced extension comparable to dietary restriction itself, while metformin produced none worth reporting. That is a serious result and it is why physicians who prescribe nothing else off-label prescribe this. Then, in April 2025, the first year-long randomized placebo-controlled trial of low-dose intermittent rapamycin in normally aging adults published its results. It enrolled 114 people, dosed them weekly for 48 weeks, and missed its primary endpoint by a distance that is difficult to misread. The secondary findings that did reach significance were mostly confined to women. For a male reader deciding whether to take this drug, the animal data and the human data are pointing in different directions, and the gap between them is the entire subject.
Key Takeaways: What the Rapamycin Evidence Actually Shows
Rapamycin raised median mouse lifespan by 23 percent in males and 26 percent in females at 42 parts per million in the diet, the highest dose the NIA Interventions Testing Program tested, with smaller gains at 14 ppm and 4.7 ppm. A 2025 systematic review and meta-analysis in Aging Cell covering eight vertebrate species concluded that rapamycin mirrors dietary restriction in lifespan effect, and that metformin does not. The PEARL trial randomized 114 adults aged 50 to 85 to placebo, 5 mg or 10 mg of compounded rapamycin once weekly for 48 weeks, and its primary endpoint of visceral adiposity did not move, at p equals 0.942. Lean tissue mass rose in women taking 10 mg weekly, by a mean difference of 6.19 kg at 48 weeks with a confidence interval from 0.88 to 11.51 and p equals 0.018, and self-reported pain improved in the same group. No efficacy outcome reached significance in the male participants, and the only statistically significant male-specific changes were laboratory values moving in unhelpful directions, including blood urea nitrogen, hemoglobin A1c and a marker of gut dysbiosis. A single oral dose of rapamycin given before high-intensity leg exercise blocked the roughly 40 percent rise in muscle protein synthesis that the exercise normally produces, which is the same pathway the drug is designed to inhibit. In male transplant recipients on continuous daily sirolimus, total sperm count averaged 28.6 million against 292.2 million in men not receiving it, and free testosterone ran lower with LH and FSH elevated. Serious adverse events in PEARL were no more common on rapamycin than on placebo, with three in the placebo arm and three across both drug arms combined.
What Is Rapamycin and What Exactly Does It Inhibit?
Rapamycin is an approved immunosuppressant, sold as sirolimus, that inhibits a protein complex called mTORC1. It was isolated from a soil bacterium found on Easter Island in the 1970s, approved in 1999 to prevent kidney transplant rejection, and only later recognized as the most reliable pharmacological life extender in laboratory mammals. mTORC1 is the cell's growth switch. When amino acids and insulin and growth factors are plentiful, mTORC1 turns on protein synthesis and cell growth and turns off autophagy, the recycling process that clears damaged proteins and organelles. When nutrients are scarce, mTORC1 shuts down and autophagy takes over. Chronic mTORC1 activation is one of the more coherent mechanistic accounts of why aging tissue accumulates junk. Rapamycin holds that switch in the off position pharmacologically, which is the same thing fasting does metabolically. There is a second complex, mTORC2, that rapamycin is not supposed to touch. In practice, prolonged continuous exposure does inhibit mTORC2 in many tissues, and mTORC2 inhibition is the accepted explanation for the glucose intolerance and insulin resistance seen with daily transplant dosing. Weekly intermittent dosing exists precisely to hit mTORC1 and let mTORC2 recover in between.
How Much Does Rapamycin Extend Lifespan in Animals?
A lot, more than any other tested compound, and the effect is dose dependent and sex dependent. The NIA Interventions Testing Program is the closest thing gerontology has to a referee, running the same protocol at three independent sites in genetically heterogeneous mice with results only accepted when they replicate. In 2009 the program reported that rapamycin started at 20 months of age, which is late middle age for a mouse, significantly raised median lifespan in both sexes. That result alone reset the field, because almost nothing works when started that late. The 2014 dose-ranging follow-up gave the numbers most people quote: at 4.7 parts per million in the diet, median lifespan rose about 3 percent in males and 16 percent in females, at 14 ppm about 13 and 21 percent, and at 42 ppm about 23 and 26 percent. Later work testing intermittent and time-limited dosing starting at 600 days found increases of 9 to 11 percent in males and 4 to 15 percent in females. Two patterns are worth holding onto. Higher doses did more. Female mice responded more strongly than male mice at every dose tested.
More Drug Bought More Life, and Females Got More of It
Percent increase in median lifespan in genetically heterogeneous mice fed rapamycin at three dietary concentrations in the NIA Interventions Testing Program, split by sex. The effect climbs with dose across the whole tested range, reaching about 23 percent in males and 26 percent in females at 42 parts per million. Female mice out-responded male mice at every dose, and the gap is widest at the low end, where males gained roughly 3 percent and females roughly 16 percent.
- Male mice
- Female mice
Is Rapamycin Better Than Caloric Restriction or Metformin?
On the animal evidence, rapamycin matches dietary restriction and metformin matches nothing. Ivimey-Cook, Sultanova and Maklakov published a systematic review and meta-analysis in Aging Cell in June 2025 that pooled lifespan outcomes across vertebrate species under three interventions: dietary restriction in both its fasting and caloric-reduction forms, metformin, and rapamycin. Across eight vertebrate species, rapamycin and dietary restriction produced comparable lifespan extension. Metformin did not produce a significant effect. This matters for anyone building a longevity protocol, because metformin has been the default off-label choice for a decade largely on the strength of observational diabetes cohorts rather than lifespan experiments. It also reframes what rapamycin is. The drug is best understood as a fasting mimetic that does not require the person to fast, which explains both why it works and why its side effect profile overlaps with the metabolic consequences of severe caloric restriction. The honest caveat is that all of this is animal lifespan data. No compound has ever been shown to extend human lifespan, and no trial capable of showing it is currently running.
Two Interventions Extended Vertebrate Lifespan. One Did Not.
A schematic reading of the 2025 systematic review and meta-analysis in Aging Cell, which pooled lifespan outcomes across eight vertebrate species under dietary restriction, rapamycin and metformin. Rapamycin produced extension comparable to dietary restriction itself. Metformin produced no significant effect. Bar height is a relative visual weight rather than a shared unit, so read this as a ranking of which interventions carried a lifespan signal, not as a percentage.
What Did the PEARL Trial Measure and What Did It Find?
PEARL measured visceral fat as its primary endpoint and visceral fat did not change, at an effect size of 0.001 and p equals 0.942. The trial, published in Aging in April 2025, randomized adults aged 50 to 85 to placebo, 5 mg or 10 mg of compounded rapamycin taken once weekly for 48 weeks, with 114 people completing and 11 discontinuing. The final groups were 39 on placebo, 40 on 5 mg and 35 on 10 mg. Three secondary outcomes reached significance. Lean tissue mass in women on 10 mg rose by a mean difference of 3.60 kg at 24 weeks and 6.19 kg at 48 weeks, with p values of 0.043 and 0.018. Self-reported pain in the same group improved by 8.07 points at 48 weeks at p below 0.001. SF-36 general health improved in the 5 mg group by 5.88 points at p equals 0.007. Emotional wellbeing also improved on 5 mg, but it improved in the placebo group too, which is the sort of finding that cancels itself. Bone mineral density, bone mineral content and WOMAC scores did not move in any group.
The Primary Endpoint Is the Bar on the Far Right
Every reported PEARL outcome plotted by its p-value, with the dashed line at the conventional threshold of 0.05. Visceral adiposity, the endpoint the trial was designed around, came in at 0.942. The three findings that cleared the threshold as benefits were self-reported pain and lean tissue mass in women taking 10 mg weekly, and SF-36 general health in the 5 mg group. The three male-specific findings that cleared it were laboratory shifts pointed the wrong way, shown in amber, all of which stayed inside normal reference ranges.
Why Did the Men in PEARL Get Nothing?
No efficacy outcome reached significance in male participants, and there are at least three plausible explanations that the trial cannot separate. The first is dose. Female mice out-respond male mice at every rapamycin dose in the ITP data, so a sex difference in humans would be consistent rather than surprising, but PEARL was not powered to test it. The second is exposure. The investigators noted that the compounded rapamycin used in the trial reached roughly one third the blood concentration of the commercial formulation at 24 hours, meaning a nominal 10 mg weekly dose delivered considerably less drug than the number implies. The third is enrollment. Women made up 35.1 percent of the trial overall and only 20 percent of the 10 mg arm, which is 8 people, so the arm where the significant findings appeared was also the arm with the fewest women in it. Small subgroups produce large effect sizes and wide confidence intervals, and the lean mass interval running from 0.88 to 11.51 kg is exactly that shape. What the men did show were isolated laboratory shifts: blood urea nitrogen rose in the 10 mg group at p equals 0.031, hemoglobin A1c rose slightly in the 5 mg group at p equals 0.024, calcium fell at p equals 0.027, and gut dysbiosis increased in the 10 mg group at p equals 0.045. All of those values stayed inside normal reference ranges. None of them is a benefit.
Does Rapamycin Blunt Muscle Growth From Training?
Acutely, yes, and this is the most directly relevant finding for men who lift. Drummond and colleagues published a study in the Journal of Physiology in 2009 in which young men took a single oral dose of rapamycin before performing high-intensity leg contractions, with muscle biopsies taken at baseline and at one and two hours after exercise. In the control group, muscle protein synthesis rose roughly 40 percent after the training bout, which is the normal anabolic response. In the rapamycin group that rise did not happen. Downstream signaling through the mTORC1 pathway was blunted or absent. This is not an unexpected side effect, it is the drug performing its stated function, since resistance exercise builds muscle largely by activating the exact complex rapamycin inhibits. What the study does not establish is what happens with weekly intermittent dosing over months, where the drug is deliberately cleared between doses and training could be scheduled several days after each dose. Nobody has run that trial. The PEARL result of lean mass rising in women on 10 mg weekly suggests weekly dosing does not simply erase muscle, but a 48-week body composition scan in untrained older adults answers a different question than a biopsy taken two hours after a set of leg extensions.
The Anabolic Response to Training, With and Without the Drug
Percent change in muscle protein synthesis after a bout of high-intensity leg contractions in young men, measured by biopsy at one and two hours, from the 2009 Journal of Physiology study. The control group showed the normal rise of roughly 40 percent. In the group given a single oral dose of rapamycin before exercise, that rise did not occur, and the mTORC1 signaling underneath it was blunted. Values are read from the reported approximate 40 percent increase and its absence on drug. No study has tested whether weekly dosing with several drug-free days before training reproduces this.
- Control
- Single dose of rapamycin
What Does Rapamycin Do to Testosterone and Fertility in Men?
Continuous daily sirolimus at transplant doses impairs male gonadal function, and this is the clearest male-specific harm signal in the literature. Zuber and colleagues reported in the American Journal of Transplantation in 2008 that male kidney transplant recipients maintained on sirolimus had a total sperm count averaging 28.6 million against 292.2 million in comparable recipients not on the drug, at p equals 0.006, with motile sperm at 22.2 percent against 41.0 percent at p equals 0.01. The rate of fathering a pregnancy was roughly 15-fold lower. Separate work in heart transplant recipients found significantly lower free testosterone alongside elevated LH and FSH, a pattern indicating the testes are being told to produce and failing to, with severity tracking drug trough levels. The mechanism is not mysterious. mTOR signaling downstream of c-kit is required for spermatogonial proliferation, and inhibiting it stops the process. The important qualifier is dose and schedule. Transplant patients take sirolimus daily, indefinitely, at trough concentrations far above anything a weekly 5 mg protocol produces, usually alongside other immunosuppressants and with impaired renal function. PEARL did not measure testosterone or semen parameters at all. That absence is the point: the one organ system with a documented male vulnerability to this drug is the system the main longevity trial did not look at.
Did mTOR Inhibition Improve Immune Function in Older Adults?
It did in two early trials and then failed in the phase 3 that was supposed to confirm it. Mannick and colleagues published in Science Translational Medicine in 2014 that the rapamycin analog everolimus, given at low dose to adults over 65 for six weeks before influenza vaccination, improved antibody response to the vaccine by roughly 20 percent and reduced the proportion of T cells expressing PD-1, a receptor that rises with age and dampens T cell function. A 2018 follow-up in the same journal reported that low-dose TORC1 inhibition reduced the rate of respiratory tract infections in older adults. On that basis resTORbio took a related compound, RTB101, into a phase 3 trial called PROTECTOR 1. In November 2019 the company announced it had missed its primary endpoint of reducing clinically symptomatic respiratory illness, and the share price fell 74 percent. There is a technical footnote that matters for how much this should update your view of rapamycin: RTB101 was originally a PI3K inhibitor with secondary mTOR activity, and unlike rapamycin it had never been shown to extend lifespan or delay age-related decline in any animal model. The phase 3 tested a different molecule, not the one with the mouse data.
What Doses Are People Taking and What Is Known About Safety?
Off-label longevity use has converged on 5 to 10 mg once weekly, which is what PEARL tested, and at that schedule the 48-week safety record was clean. Serious adverse events were no more common on drug than placebo, with one in the 10 mg arm, two in the 5 mg arm and three in placebo. Total non-severe adverse events were essentially identical across arms at 117, 116 and 122. The proportion of participants reporting any adverse event was actually lowest in the 10 mg group at 80.6 percent against 87.2 percent on placebo. Gastrointestinal symptoms were the one consistent excess on drug, at 8 and 7 cases against 4. One participant on 5 mg developed anemia requiring transfusion, which resolved. Epigenetic age testing in a subset of 24 participants showed no meaningful change in either direction. Three practical limitations deserve weight. Compounded rapamycin delivered about a third the blood level of the commercial product, so potency varies with the pharmacy. Mouth ulcers and lipid elevation are the classic dose-limiting effects at higher exposures and were not prominent here. And 48 weeks is the longest randomized human exposure anyone has published for this indication, which says nothing about a decade of use.
How Should the Whole Rapamycin Evidence Base Be Read?
Rapamycin has the best animal longevity data of any molecule and one year of human data that mostly failed to find what it went looking for. Both of those statements are true and they are not in conflict. The mouse work is large, replicated across independent sites, dose dependent and effective when started late in life, which is a combination no supplement in this category can approach. The 2025 vertebrate meta-analysis extends that pattern beyond rodents. Against that, PEARL missed its primary endpoint outright, its positive findings sat in a subgroup of 8 women, and its male participants finished the year with no measured benefit and a handful of laboratory values pointed the wrong way. For a man weighing this, three things should govern the decision. There is currently no randomized evidence that weekly rapamycin improves any measured outcome in men. There is randomized evidence that a single dose blocks the muscle protein synthesis response to training. There is observational evidence from continuous high-dose use that mTOR inhibition suppresses spermatogenesis and lowers free testosterone, which is a real consideration for any man who wants children. The trial that would settle this is TRIAD, the Test of Rapamycin in Aging Dogs, which is enrolling 580 dogs aged 7 and older for one year of dosing and two years of follow-up with lifespan and healthspan as actual endpoints. Dosing was expected to begin in spring 2026. It is the first properly powered test of this drug against aging outside a laboratory, in any species, and it will report years before anything comparable exists in people.
The Rapamycin Record on One Axis
Every strand of the evidence arranged as a single schematic map. Indigo marks what the animal and randomized human data support, amber marks findings that are real but cut against a male longevity user, and grey marks claims the evidence does not carry. Bar length is a rough visual weight rather than a shared unit. The animal lifespan record sits at the strong end and is the reason anyone takes this drug. The male human record sits at the weak end and is the reason to be careful about when.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.